Witnessing the stock’s movement on the chart, on Thursday, Candel Therapeutics Inc (NASDAQ: CADL) set off with pace as it heaved 10.61% to $4.90, before settling in for the price of $4.43 at the close. Taking a more long-term approach, CADL posted a 52-week range of $0.77-$14.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -25.00%. Meanwhile, its Annual Earning per share during the time was -46.75%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -25.95%. This publicly-traded company’s shares outstanding now amounts to $32.13 million, simultaneously with a float of $19.97 million. The organization now has a market capitalization sitting at $159.13 million. At the time of writing, stock’s 50-day Moving Average stood at $5.40, while the 200-day Moving Average is $5.81.
Candel Therapeutics Inc (CADL) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Candel Therapeutics Inc’s current insider ownership accounts for 38.50%, in contrast to 14.78% institutional ownership. According to the most recent insider trade that took place on Nov 29 ’24, this organization’s Chief Technology Officer sold 20,392 shares at the rate of 4.56, making the entire transaction reach 92,898 in total value, affecting insider ownership by 125,657. Preceding that transaction, on Nov 29 ’24, Company’s Chief Executive Officer sold 48,847 for 4.56, making the whole transaction’s value amount to 222,527. This particular insider is now the holder of 294,788 in total.
Candel Therapeutics Inc (CADL) Earnings and Revenue Records
Candel Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -25.95% and is forecasted to reach 0.15 in the upcoming year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Let’s observe the current performance indicators for Candel Therapeutics Inc (CADL). It’s Quick Ratio in the last reported quarter now stands at 1.18. The Stock has managed to achieve an average true range (ATR) of 0.46.
In the same vein, CADL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.74, a figure that is expected to reach -0.30 in the next quarter, and analysts are predicting that it will be 0.15 at the market close of one year from today.
Technical Analysis of Candel Therapeutics Inc (CADL)
Going through the that latest performance of [Candel Therapeutics Inc, CADL]. Its last 5-days volume of 0.66 million was inferior to the volume of 1.75 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 38.66% While, its Average True Range was 0.49.
Raw Stochastic average of Candel Therapeutics Inc (CADL) in the period of the previous 100 days is set at 24.53%, which indicates a major fall in contrast to 62.46% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 119.12% that was higher than 75.38% volatility it exhibited in the past 100-days period.
